在阿尔茨海默病患者中氨酸过氧化酶活性:系统性审查和元分析
Meire Ellen Pereira1,2, Júlia Vicentin de Souza1,2, Gabriella Giandotti Gomar2
1Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Paraná, Brazil.
Journal of Alzheimer's disease : JAD
|June 2, 2025
概括
在阿尔茨海默病 (AD) 患者中,氨酸过氧化酶 (GPX) 活性下降,这表明氧化应激和AD进展之间存在联系. 需要进一步的研究来澄清GPX在认知衰退中的作用.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 老年学是一门学科.
背景情况:
- 氧化应激是阿尔茨海默病 (AD) 发展和恶化的已知因素.
- 氨酸过氧化酶 (GPX) 通过调节过氧化水平,在控制氧化压力方面发挥着至关重要的作用.
研究的目的:
- 在阿尔茨海默病 (AD) 患者中系统地审查和元分析谷氨过氧化酶 (GPX) 活性.
- 评估GPX活性与AD中氧化应激标志物之间的关系.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 将队列和病例控制研究纳入到2024年12月.
- 使用纽卡斯尔-太华尺度和RevMan.Man的统计分析进行偏差风险评估.
主要成果:
- 30项研究被纳入系统性审查,其中20项用于元分析.
- 在红细胞,血和脑组织中测量GPX活性.
- 与健康对照人群相比,在AD患者中,红细胞和血GPX活性通常被抑制.
结论:
- 在大多数研究中,阿尔茨海默病 (AD) 患者的GPX活性下降.
- 需要进一步调查以阐明减少GPX活性对AD相关认知障碍和氧化应激的影响.
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686